Business Wire

New NIQ Report: Quality, Convenience, and Hygiene to Drive Growth in Home Appliances Market in 2026

15.10.2025 15:00:00 CEST | Business Wire | Press Release

Share

NielsenIQ (NYSE: NIQ) today released its Home Appliances Outlook 2026: What consumers want report, which reveals the macro forces that will shape the Home Appliances industry in 2026 and the product innovation most likely to drive growth.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015103990/en/

NIQ projects a 2% year-over-year sales growth between 2024 and 2025 for global Consumer Tech and Durable Goods (T&D), with household appliances playing a significant part in that growth.

Global sales of T&D products overall grew 4.6% in the first half of 2025 compared with the same period in 2024, with consumers spending more per item in all sectors except Major Domestic Appliances (MDA). Consumers remain cautious in their spending but are willing to pay for appliances that offer smart convenience, multifunctionality, energy efficiency, or health and hygiene benefits.

New Market Realities Reshape the Home Appliances Landscape

  • China’s International Push: In the first half of this year, Chinese brands grew their global market share by 40.1% for sales of Small Domestic Appliances (SDA), driven by product innovation, and 23.5% for sales of MDA, driven by competitive pricing.
  • Trade-In Momentum: China’s household appliance trade-in policy continues to drive sales. At the end of 2024, a NIQ survey of 24,000 consumers in China found that 71%had used the subsidies to upgrade their appliances.
  • Tariff Impact: US tariffs of 50% on “steel equivalents” in major domestic appliances imported into the US went into effect in late June 2025. This factor is likely to depress US demand for overseas brands, causing those brands to look to expand their presence in other markets to make up for lost revenue.
  • Gen X Power: Gen X, the highest-spending consumer generation for the next five years, is prioritizing durability, quality, and energy savings—79% are focused on conserving energy at home. As “caretaker consumers” balancing multi-generational needs, Gen Xers are a high-priority audience for home appliances.
  • Replacement Cycles: For SDA, replacement cycles average five to six years. The commoditization of recent innovation in small appliances has lowered price points, encouraging consumers to upgrade their existing appliances to smarter, more premium ones. For MDA, a replacement surge is expected in 2028.

“The convergence of value-driven consumer behavior, global trade shifts, and digital transformation is creating new opportunities—and risks—for appliance manufacturers and retailers. Strategic agility will be essential to capture growth in this evolving landscape,” said Julian Baldwin, President, Global Tech & Durables, NIQ.

The report also explores several trends that will drive demand for home appliances in 2026, including:

  • Maximizing Omnichannel Potential: Consumers move freely across the full mix of channels to solve their product research and buying needs. Online dominates SDA sales (51% globally, rising to 95% in China), while MDA online sales have grown to 30% of global salesin the first half of this year. In addition, 39% of consumers who research a product both online and offline are more likely to spend more than intended when they buy—regardless of where that final purchase is made.
  • Sustainability Surge: As of 2025, 45% of consumers now consider environmental impact when purchasing. Energy efficiency is atop driver for MDA purchases, with 90% of lifetime energy use occurring during product usage. In 2026, energy efficiency will continue to be the leading purchase driver for MDA shoppers.
  • Health Focus: Hygiene-related appliances like vacuum cleaners, washing machines, and dishwashers saw a 6% sales growth in the first half of this year, outpacing overall T&D value growth. Added to this, 74% of consumers say they prefer tech with health and wellness features over ones without, and 44% cite healthier cooking as a key driver for wanting to buy health tech appliances.

Download the full report for more details and guidance for brands on where to invest in product innovation, assortment, and marketing in the year ahead.

About the report:
NIQ’s Home Appliances Outlook 2026: What consumers want report is the latest in NIQ’s industry-renowned global State of Tech & Durables series. It specifically examines consumer purchase trends in the Home Appliances sector, making clear predictions about the key innovation and market approaches that manufacturers and retailers will need for a successful 2026. A Regional Insights Companion explores the expected regional growth for major and small domestic appliances in Asia Pacific; Eastern Europe, Middle East & Africa; Latin America; North America; and Western Europe.

About NIQ:
NielsenIQ (NIQ) is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. Our global reach spans over 90 countries covering approximately 85% of the world’s population and more than $7.2 trillion in global consumer spend. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full View™. For more information, please visit niq.com

© 2025 Nielsen Consumer LLC. All Rights Reserved.

Forward-Looking Statements Disclaimer
This press release may contain forward-looking statements regarding anticipated consumer behaviors, market trends, and industry developments. These statements reflect current expectations and projections based on available data, historical patterns, and various assumptions. Words such as “expects,” “anticipates,” “projects,” “believes,” “forecasts,” and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future outcomes and are subject to inherent uncertainties, including changes in consumer preferences, economic conditions, technological advancements, and competitive dynamics. Actual results may differ materially from those expressed or implied in these statements. While we strive to base our insights on reliable data and sound methodologies, we undertake no obligation to update any forward-looking statements to reflect future events or circumstances, except to the extent required by applicable law.

NIQ-GENERAL

View source version on businesswire.com: https://www.businesswire.com/news/home/20251015103990/en/

Contacts

Media Contact: media.relations@niq.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye